Efficacy of Linvoseltamab in Prespecified High Risk Subgroups of Patients with Relapsed/Refractory Multiple Myeloma: Results from LINKER-MM1

被引：0

作者：

Suvannasankha, Attaya ^{[1
,2
]}

Lee, Hans ^{[3
]}

Bumma, Naresh ^{[4
]}

Dhodapkar, Madhav V. ^{[5
]}

Richter, Joshua ^{[6
]}

Hoffman, James E. ^{[7
]}

Shah, Mansi ^{[8
]}

Lentzsch, Suzanne ^{[9
]}

Zonder, Jeffrey ^{[10
]}

Baz, Rachid ^{[11
]}

Maly, Joseph J. ^{[12
]}

Namburi, Swathi ^{[13
]}

Wu, Ka Lung ^{[14
]}

Pianko, Matthew ^{[15
]}

Silbermann, Rebecca ^{[16
]}

Min, Chang-Ki ^{[17
]}

Vekemans, Marie-Christiane ^{[18
]}

Munder, Markus ^{[19
]}

Martinez Lopez, Joaquin ^{[20
]}

DeVeaux, Michelle ^{[21
]}

Chokshi, Dhruti ^{[21
]}

Boyapati, Anita ^{[21
]}

Kroog, Glenn S. ^{[21
]}

Houvras, Yariv ^{[21
]}

Jagannath, Sundar ^{[22
]}

机构：

[1] Indiana Univ, Simon Canc Ctr, Indianapolis, IN USA

[2] Roudebush VAMC, Indianapolis, IN USA

[3] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[4] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA

[5] Emory Univ, Sch Med, Atlanta, GA USA

[6] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

[7] Univ Miami Hlth Syst, Miami, FL 33125 USA

[8] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA

[9] Columbia Univ, Med Ctr, New York, NY USA

[10] Karmanos Canc Inst, Detroit, MI 48201 USA

[11] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[12] Norton Canc Inst, Louisville, KY USA

[13] Swedish Canc Inst, Seattle, WA USA

[14] ZNA Cadix, Antwerp, Belgium

[15] Univ Michigan Hlth, Rogel Canc Ctr, Ann Arbor, MI USA

[16] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR USA

[17] Catholic Univ Korea, St Marys Hosp, Seoul, South Korea

[18] Univ Catholic Louvain UCLouvain, Clin Univ St Luc, Dept Hematol, Brussels, Belgium

[19] Univ Med Ctr Mainz, Dept Internal Med 3, Mainz, Germany

[20] Univ Complutense, Hosp 12 Octubre, CNIO, Sch Med ,i 12, Madrid, Spain

[21] Regeneron Pharmaceut Inc, Tarrytown, NY USA

[22] Mt Sinai Med Ctr, New York, NY USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-084

引用

页码：S90 / S91

页数：2

共 50 条

[1] Efficacy and safety of linvoseltamab 200 mg in patients with relapsed/refractory multiple myeloma (RRMM): analysis of the LINKER-MM1 study
Dhodapkar, Madhav
Bumma, Naresh
Richter, Joshua
Lee, Hans
Hoffman, James
Suvannasankha, Attaya
Lentzsch, Suzanne
Shah, Mansi
Zonder, Jeffrey
Baz, Rachid
Wu, Ka Lung
Pianko, Matthew
Silbermann, Rebecca
Min, Chang-Ki
Vekemans, Marie-Christiane Madeleine
Munder, Markus
Byun, Ja Min
Martinez Lopez, Joaquin
DeVeaux, Michelle
Lorenc, Karen Rodriguez
Kroog, Glenn
Houvras, Yariv
Jagannath, Sundar
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S172 - S172
[2] Pharmacokinetics (PK) and Immunogenicity of Linvoseltamab in Patients (pts) with Relapsed/ Refractory Multiple Myeloma (RRMM) in LINKER-MM1
Hazra, Anasuya
Lai, Ching-Ha
Chokshi, Dhruti
Houvras, Yariv
Kroog, Glenn S.
Lorenc, Karen Rodriguez
DiCioccio, A. Thomas
Davis, John
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S57 - S57
[3] LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma.
Lee, Hans C.
Bumma, Naresh
Richter, Joshua Ryan
Dhodapkar, Madhav V.
Hoffman, James E.
Suvannasankha, Attaya
Zonder, Jeffrey A.
Shah, Mansi R.
Lentzsch, Suzanne
Maly, Joseph J.
Ye, Jing Christine
Wu, Ka Lung
DeVeaux, Michelle
Chokshi, Dhruti
Boyapati, Anita
Hazra, Anasuya
Rodriguez-Lorenc, Karen
Kroog, Glenn Scott
Houvras, Yariv J.
Jagannath, Sundar
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[4] Patterns of Response to 200 Mg Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-Up of the Linker-MM1 Study
Jagannath, Sundar
Richter, Joshua
Dhodapkar, Madhav V.
Hoffman, James E.
Lee, Hans C.
Suvannasankha, Attaya
Shah, Mansi R.
Lentzsch, Suzanne
Zonder, Jeffrey A.
Baz, Rachid
Maly, Joseph J.
Namburi, Swathi
Wu, Ka Lung
Pianko, Matthew
Ye, Jing Christine
Silbermann, Rebecca
Min, Chang-Ki
Vekemans, Marie-Christiane
Munder, Markus
Byun, Ja Min
BLOOD, 2023, 142
[5] Assessment of health-related quality of life (HRQoL) in triple-class-exposed patients with relapsed or refractory multiple myeloma (RRMM) treated with linvoseltamab in the LINKER-MM1 trial
Hoffman, James E.
Bumma, Naresh
Richter, Joshua Ryan
Dhodapkar, Madhav V.
Lee, Hans C.
Suvannasankha, Attaya
Zonder, Jeffrey A.
Maly, Joseph J.
Shah, Mansi R.
Baz, Rachid C.
DeVeaux, Michelle
Ivanescu, Cristina
Rodriguez-Lorenc, Karen
Kroog, Glenn Scott
Houvras, Yariv J.
Inocencio, Timothy J.
Chi, Lei
Harnett, James
Ma, Qiufei
Jagannath, Sundar
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[6] Evaluation of the efficacy and safety of two different linvoseltamab Phase 2 dose regimens: results from LINKER-MM1
Richter, Joshua
Bumma, Naresh
Dhodapkar, Madhav
Hoffman, James
Lee, Hans
Suvannasankha, Attaya
DeVeaux, Michelle
Chokshi, Dhruti
Boyapati, Anita
Hazra, Anasuya
Lorenc, Karen Rodriguez
Kroog, Glenn
Houvras, Yariv
Jagannath, Sundar
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S58 - S59
[7] Health-Related Quality of Life (HRQoL) Among Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Linvoseltamab in Linker-MM1: Interim Assessment up to 36 Weeks of Treatment
Hoffman, James E.
Bumma, Naresh
Richter, Joshua
Dhodapkar, Madhav V.
Lee, Hans C.
Suvannasankha, Attaya
Houde, Christiane A.
Maly, Joseph J.
Shah, Mansi R.
Baz, Rachid
Namburi, Swathi
Wu, Ka Lung
Pianko, Matthew
Ye, Jing Christine
Lentzsch, Suzanne
Silbermann, Rebecca
Min, Chang-Ki
Vekemans, Marie-Christiane
Munder, Markus
Byun, Ja Min
Martinez Lopez, Joaquin
DeVeaux, Michelle
Ivanescu, Cristina
Lorenc, Karen Rodriguez
Kroog, Glenn S.
Houvras, Yariv
Inocencio, Timothy J.
Chi, Lei
Harnett, James
Ma, Qiufei
Jagannath, Sundar
BLOOD, 2023, 142
[8] Efficacy and safety of bortezomib in patients with refractory and relapsed multiple myeloma (MM) outside clinical trials: Results from the catalan myeloma/amyloid study group (Gemmac)
Cibeira, M. T.
Garcia, A.
Rosinol, L.
Petit, J.
Oriol, A.
Abella, E.
Soler, J. A.
Plensa, E.
Callis, M.
Gonzalez, Y.
Macia, J.
Orriols, J.
Escoda, L.
Tutusaus, M.
Heras, G.
Monzo, S.
Herranz, M. J.
Garcia, M.
Sureda, A.
Blade, J.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 157 - 157
[9] Selinexor, daratumumab, and dexamethasone in patients with relapsed/refractory multiple myeloma (MM).
Gasparetto, Cristina
Lentzsch, Suzanne
Schiller, Gary J.
Callander, Natalie Scott
Tuchman, Sascha
Bahlis, Nizar J.
White, Darrell
Chen, Christine
Baljevic, Muhamed
Sutherland, Heather J.
Kotb, Rami
Sebag, Michael
LeBlanc, Richard
Venner, Christopher P.
Bensinger, William
Rossi, Adriana C.
Sheehan, Heidi
Arazy, Melina
Kai, Kazuharu
Lipe, Brea
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[10] LINKER-MM3, a phase 3, open-label, randomized study of linvoseltamab versus elotuzumab, pomalidomide, and dexamethasone (EPd) in relapsed/refractory multiple myeloma (RRMM)
Weisel, Katja
Hungria, Vania
Quach, Hang
Yoon, Sung-Soo
Rodriguez-Otero, Paula
Sinha, Arijit
Boyapati, Anita
Lyon, Charlotte
Moore, Vygngley
Inocencio, Tim
Harnett, James
Chi, Lei
Lorenc, Karen Rodriguez
Kroog, Glenn
Voorhees, Peter
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S63 - S64

← 1 2 3 4 5 →